Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP

Hematology

Volumn 21, Issue 9, 2016, Pages 552-557

  Zhong, Jun ^a   Chen, Shaohua ^b   Xu, Ling ^b   Lai, Jing ^a   Liao, Ziwei ^b   Zhang, Tao ^a   Yu, Zhi ^a   Lu, Yuhong ^a   Yang, Lijian ^b   Wu, Xiuli ^b   Li, Bo ^b   Li, Yangqiu ^a,b  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

CTLA 4; Immune thrombocytopenic purpura; PD 1; PD L1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BLOOD; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD274; CTLA-4 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 84978529058     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245332.2016.1155347     Document Type: Article

References (39)

1. R.Aslam, Y.Hu, S.Gebremeskel, G.B.Segel, E.R.Speck, L.Guo, Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood. 2012;120(10):2127–32. doi:10.1182/blood-2012-02-413526
2. X.Chen, S.Chen, C.Li, Y.Zhu, B.Peng. Skewed T-cell subsets and enhanced macrophages phagocytosis in the spleen of patients with immune thrombocytopenia failing glucocorticoids. Int J Hematol. 2011;94(3):248–54. doi:10.1007/s12185-011-0908-6
3. D.B.Cines, A.Cuker, J.W.Semple. Pathogenesis of immune thrombocytopenia. Presse Med. 2014;43(4 Pt 2):e49–59. doi:10.1016/j.lpm.2014.01.010
4. C.G.McKenzie, L.Guo, J.Freedman, J.W.Semple. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163(1):10–23. doi:10.1111/bjh.12480
5. J.Thachil. Alternate considerations for current concepts in ITP. Hematology. 2014;19(3):163–8. doi:10.1179/16078454137.0000000104
6. X.L.Zhang, Y.Q.Li, S.H.Chen, L.J.Yang, S.Chen, X.L.Wu, The feature of clonal expansion of TCR Vβ repertoire, thymic recent output function and TCRζ chain expression in patients with immune thrombocytopenic purpura. Int J Lab Hematol. 2009;31(6):639–48. doi:10.1111/j.1751-553X.2008.01091.x
7. X.L.Zhang, J.Peng, J.Z.Sun, J.J.Liu, C.S.Guo, Z.G.Wang, De novo induction of platelet-specific CD4+CD25+ regulatory T cells from CD4+CD25- cells in patients with idiopathic thrombocytopenic purpura. Blood. 2009;113(11):2568–77. doi:10.1182/blood-2008-03-148288
8. N.Arandi, A.Mirshafiey, M.Jeddi-Tehrani, M.Shaghaghi, B.Sadeghi, H.Abolhassani, Alteration in frequency and function of CD4(+)CD25(+)FOXP3(+) regulatory T cells in patients with immune thrombocytopenic purpura. Iran J Allergy Asthma Immunol. 2014;13(2):85–92.
9. S.Audia, M.Samson, M.Mahevas, C.Ferrand, M.Trad, M.Ciudad, Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 2013;122(14):2477–86. doi:10.1182/blood-2013-03-491415
10. Y.Hu, H.Li, L.Zhang, B.Shan, X.Xu, H.Li, Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol. 2012;73(6):629–35. doi:10.1016/j.humimm.2012.04.015
11. J.W.Semple, D.Provan. The immunopathogenesis of immune thrombocytopenia:T cells still take center-stage. Curr Opin Hematol. 2012;19(5):357–62. doi:10.1097/MOH.0b013e3283567541
12. J.W.Semple, D.Provan, M.B.Garvey, J.Freedman. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010;17(6):590–5. doi:10.1097/MOH.0b013e32833eaef3
13. I.Song, J.Kim, K.Kwon, S.Koo, D.Jo. Expression of CD154 (CD40L) on stimulated T lymphocytes in patients with idiopathic thrombocytopenic purpura. Hematology. 2015 Jul 17. [Epub ahead of print].
14. S.Q.Xu, C.Y.Wang, X.J.Zhu, X.Y.Dong, Y.Shi, J.Peng, Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia. Ann Hematol. 2012;91(10):1623–31. doi:10.1007/s00277-012-1451-0
15. S.Fujita, T.Nakanishi, H.Yoshimura, M.Hotta, N.Nakamichi, T.Tamaki, TGFβ1 and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. Thromb Res. 2012;130(3):415–9. doi:10.1016/j.thromres.2012.06.002
16. X.Ji, L.Zhang, J.Peng, M.Hou. T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol. 2014;7:72. doi:10.1186/s13045-014-0072-6
17. J.Kiyasu, H.Miyoshi, A.Hirata, F.Arakawa, A.Ichikawa, D.Niino, Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193–201. doi:10.1182/blood-2015-02-629600
18. A.Y.Lin, E.Lin. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol. 2015;8(1):124. doi:10.1186/s13045-015-0222-5
19. L.Shi, S.Chen, L.Yang, Y.Li. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74. doi:10.1186/1756-8722-6-74
20. M.Pavkovic, B.Georgievski, L.Cevreska, M.Spiroski, D.G.Efremov. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol. 2003;72(2):147–9. doi:10.1002/ajh.10278
21. X.L.Zhang, J.Peng, J.Z.Sun, C.S.Guo, Y.Yu, Z.G.Wang, Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost. 2008;6(1):158–65. doi:10.1111/j.1538-7836.2007.02804.x
22. D.Schubert, C.Bode, R.Kenefeck, T.Z.Hou, J.B.Wing, A.Kennedy, Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6. doi:10.1038/nm.3746
23. E.R.Radwan, R.L.Goda. Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of Egyptian childhood immune thrombocytopenic purpura. Clin Appl Thromb Hemost. 2015;21(4):378–82. doi:10.1177/1076029613502254
24. H.Li, J.Ge, H.Zhao, W.Du, J.Xu, T.Sui, Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population. Platelets. 2011;22(1):39–44. doi:10.3109/09537104.2010.521601
25. G.Goel, W.Sun. Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade. J Hematol Oncol. 2015;8:86. doi:10.1186/s13045-015-0185-6
26. F.M.Schnorfeil, F.S.Lichtenegger, K.Emmerig, M.Schlueter, J.S.Neitz, R.Draenert, T cells are functionally not impaired in AML:increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93. doi:10.1186/s13045-015-0189-2
27. T.Kohnke, C.Krupka, J.Tischer, T.Knosel, M.Subklewe. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8(1):111. doi:10.1186/s13045-015-0213-6
28. E.B.Atesoglu, P.Tarkun, E.T.Demirsoy, A.Geduk, O.Mehtap, A.Batman, Soluble programmed death 1 (PD-1) is decreased in patients with immune thrombocytopenia (ITP):potential involvement of PD-1 pathway in ITP immunopathogenesis. Clin Appl Thromb Hemost. 2014; 22(3):248–51.
29. C.Neunert, W.Lim, M.Crowther, A.Cohen, L.SolbergJr, M.A.Crowther; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207. doi:10.1182/blood-2010-08-302984
30. L.Shi, S.Chen, X.Zha, Y.Xu, L.Xu, L.Yang, Enhancement of the TCRζ expression, polyclonal expansion, and activation of t cells from patients with acute myeloid leukemia after IL-2, IL-7, and IL-12 induction. DNA Cell Biol. 2015;34(7):481–8. doi:10.1089/dna.2015.2810
31. S.Chen, X.Zha, L.Shi, L.Zhou, L.Yang, B.Li, Upregulated TCRζ improves cytokine secretion in T cells from patients with AML. J Hematol Oncol. 2015;8:72. doi:10.1186/s13045-015-0170-0
32. M.Grzywnowicz, J.Zaleska, D.Mertens, W.Tomczak, P.Wlasiuk, K.Kosior, Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One. 2012;7(4):e35178. doi:10.1371/journal.pone.0035178
33. Z.Liao, L.Zhou, C.Wang, Z.He, X.Wang, X.Luo, Characteristics of TCRζ, ZAP-70, and FcϵRIγ gene expression in patients with T- and NK/T-cell lymphoma. DNA Cell Biol. 2015;34(3):201–7. doi:10.1089/dna.2014.2693
34. W.A.Stams, M.L.den Boer, H.B.Beverloo, J.P.Meijerink, R.L.Stigter, E.R.van Wering, Sensitivity to l-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101(7):2743–7. doi:10.1182/blood-2002-08-2446
35. S.Chen, S.Liu, L.Xu, L.Yang, Z.Jin, Y.Ma, The characteristic expression pattern of BMI-1 and SALL4 genes in placenta tissue and cord blood. Stem Cell Res Ther. 2013;4(2):49. doi:10.1186/scrt199
36. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690
37. L.Yu, C.Zhang, L.Zhang, Y.Shi, X.Ji. Biomarkers for immune thrombocytopenia. Biomark Res. 2015;3:19. doi:10.1186/s40364-015-0045-0
38. X.M.Zhang, N.N.Shan, M.Sun, X.Wang, X.M.Feng, X.Liu, Imbalanced expression of human Tim-1 and Tim-3 in peripheral blood mononuclear cells from immune thrombocytopenia patients. Int Immunopharmacol. 2014;19(1):1–4. doi:10.1016/j.intimp.2013.12.025
39. L.Xu, Y.Zhang, G.Luo, Y.Li. The roles of stem cell memory T cells in hematological malignancies. J Hematol Oncol. 2015;8(1):113. doi:10.1186/s13045-015-0214-5